Registration for this event has been disabled.


Hong Kong served as the top IPO fundraising center for 6 out of the past 10 years and ranked second in 2020 for IPO proceeds (with a 24% boost in fundraising). Listing reforms from 2018 introduced weighted voting rights and biotech listing regulation reform aimed to diversify Hong Kong's concentrated capital market. In this session, we will explore how the capital market regulatory environment and innovations in market structure can continue to be enhanced. This will ensure the city remains a destination of choice for primary listings across a range of companies, and secondary markets trading, with deep and robust market liquidity.